Table 1.
Epitope Selection: Sequences of the peptide mimics used in this manuscript are shown above. In this study, we used five novel B cell epitopes that have been previously characterized in our laboratory and include one HER-1 epitope (HER-1-418-435), two HER-2 epitopes (HER-2-266-296 and HER-2-597-626), and two IGF-1R epitopes (IGF-1R-56-81 and IGF-1R-233-251). These epitopes were designed based on the ligand binding site of the receptor using crystallographic structures, mutagenesis studies, and models of the complex between the receptor ligand interactions. Sequences are also shown for the chimeric B-cell epitope vaccines engineered with the “promiscuous” T cell epitope of the measles virus fusion protein (MVF; italics). The flexible linker sequence GPSL was used in collinearly synthesizing the vaccines with MVF and is underlined in the table; molecular weights for each inhibitor are indicated.
| Peptides | Amino Acid Sequence of HER-1,HER-2 and IGF-1R Peptides | Mol.Wt (Da) |
|---|---|---|
| HER-1 (418–435) | Ac-SLNITSLGLRSLKEISDG-OH | 1944 |
| HER-2 (266–296) | LHCPALVTYNTDTFESMPNPEGRYTFGASCV-OH | 3420 |
| HER-2 (597–626) | VARCPSGVKPDLSYMPIWKFPDEEGACQPL-OH | 3333 |
| IGF-1R (56–81) | Ac-LLFRVAGLESLGDLFPNLTVIRGWKL-NH2 | 2969 |
| IGF-1R (233–251) | Ac-ACPPNTYRFEGWRCVDRDF-NH2 | 2372 |
| MVF-HER-1 (418–435) | KLLSLIKGVIVHRLEGVE-GPSL-SLNITSLGLRSLKEISDG-OH | 4242 |
| MVF-HER-2 (266–296) | KLLSLIKGVIVHRLEGVE-GPSL-LHCPALVTYNTDTFESMPNPEGRYTFGASCV-OH | 5757 |
| MVF-HER-2 (597–626) | KLLSLIKGVIVHRLEGVE-GPSL-VARCPSGVKPDLSYMPIWKFPDEEGACQPL-OH | 5672 |
| MVF-IGF-1R (56–81) | KLLSLIKGVIVHRLEGVE-LSPG-LLFRVAGLESLGDLFPNLTVIRGWKL-NH2 | 5267 |
| MVF-IGF-1R (233–251) | Ac-KLLSLIKGVIVHRLEGVE-GPSL-Ac-ACPPNTYRFEGWRCVDRDF-NH2 | 4712 |